Huami Corp Invests $5 Million in Hyperfine Research D Round to Support Accelerated Application of Disruptive MRI Technology
11 2월 2021 - 12:05AM
Business Wire
Huami Corp. (NYSE: HMI) today announced that it has invested $5
million in Hyperfine Research’s D round of funding, which closed on
February 3, 2021. Huami’s mission is to connect health with
technology, developing both consumer and industrial health
technologies. The company believes its miniaturization engineering
expertise dovetails with efforts to miniaturize medical imaging
technology which can disrupt the locations, applications and costs
of medical imaging. Hyperfine Research is pioneering MRI imaging
with its portable Swoop system, which received FDA 510(K) clearance
in August of 2020.
“In the same way that new depth and granularity of data from
wearable devices has changed health population management, we see
the miniaturization of imaging technology changing the places and
speed at which clinicians can evaluate patients,” said Huami’s
chief operating officer, Mike Yeung. “We are excited to participate
with Hyperfine in support of their mission.”
About Huami Corporation
Huami’s mission is to connect health with technology. Since its
inception in 2013, Huami has developed a platform of proprietary
technology including AI chips, biometric sensors, and data
algorithms, which drive a broadening line of smart health products
for consumers, and analytics services for industry. In 2019, Huami
shipped 36.6 million units of smart watches and fitness bands,
including its own Amazfit brand, and products developed and
manufactured for Xiaomi, comprising 23% of global category
shipments1. Huami Corporation is based in Hefei, China, with U.S.
operations, Huami-USA, based in Cupertino, Calif. For more
information, please visit
https://www.huami.com/investor/pages/company-profile.
1 IDC, Correcting and Replacing Shipments of Wearable Devices,
3/10/20
About Hyperfine Research: Hyperfine’s mission is to make
MR imaging available to everyone. The
Swoop™ Portable MR Imaging System is the result of a total rethink
of MR’s potential in the healthcare landscape. What if MR imaging
didn’t require a dedicated suite, extensive training or expensive
upkeep? The wonders of high-field MRI can be used for the
appropriate patients, and Swoop™ can be deployed at the
point-of-care for everyone else. Hyperfine received market-ready
FDA clearance for its portable MR imaging for the brain and head of
patients of all ages in August 2020. Since its launch in the fall
of 2020, Swoop has been honored repeatedly, as one of two finalists
for the Best New Radiology Vendor of 2020 by Aunt Minnie, the
winner of the American College of Emergency Physicians (ACEP) 2020
incubatED Medical Device Innovation Challenge, and with a Best
Practices Product Innovation Award from Frost & Sullivan, and
most recently as a 2021 Innovation Awards Honoree from CES.
Hyperfine is part of 4Catalyzer, a health technology incubator with
offices in CT, NY, CA and Taiwan. www.hyperfine.io.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210210005142/en/
For Huami media inquiries: Lydia Huang,
lydia.huang@huami-usa.com, c: 407-800-5625
For Huami investors: U.S. - Brad Samson,
brad.samson@huami-usa.com, c: 714-955-3951 China – Grace Zhang,
zhangyujia@huami.com
For Hyperfine Research media inquiries: Chris Ward,
cward@hyperfine.io, (203) 905-0412
Huami (NYSE:HMI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Huami (NYSE:HMI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024